MANTLE CELL LYMPHOMA (MCL)

This study tests a combination of two treatments—an immune cell therapy (relmacabtagene autoleucel) and an immunotherapy drug (sintilimab)—in 30 adults with relapsed or refractory B-cell lymphoma (including diffuse large B-cell, mantle cell, and follicular lymphoma). The goal is …

This study is for people with a fast-growing type of blood cancer called mantle cell lymphoma that has not been treated yet. It tests a combination of three drugs (orelabrutinib, lisaftoclax, and rituximab) to see how well they shrink tumors and how safe they are. About 25 partic…

This study tests a new combination of two drugs (pirtobrutinib and rituximab) as a first treatment for people with a slow-growing form of mantle cell lymphoma, a type of blood cancer. The goal is to see if this drug pair can shrink tumors without the need for standard chemotherap…

This early-phase study tests a new type of cell therapy (CD19x22 CAR T) for adolescents and adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to target two proteins on cancer cells. Th…

This study is for people newly diagnosed with a type of blood cancer called mantle cell lymphoma that is not considered high-risk. It tests a combination of two drugs (orelabrutinib and rituximab) and may include a stem cell transplant using the patient's own cells. The goal is t…

This study tests a combination of three drugs (pomalidomide, orelabrutinib, and zuberitamab) in people with untreated mantle cell lymphoma, a type of blood cancer. The goal is to see if the treatment can reduce cancer cells to undetectable levels after six cycles. Patients who re…

This early-stage study tests a new drug called NX-2127 in adults with certain blood cancers (like CLL or lymphoma) that have returned or not improved after other treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About …

This study tests an experimental drug called NX-5948 in adults with certain blood cancers (like CLL or lymphoma) that have come back or stopped responding to treatment. The drug works by breaking down a protein that helps cancer cells grow. The main goals are to find a safe dose …

This study tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells, aiming to treat adults with B-cell blood cancers like lymphoma and leukemia that have not responded to other treatments. The therapy uses the patient's own immune cells, w…

This early-phase study tests a new drug called LTZ-301 in 42 adults with certain types of non-Hodgkin lymphoma that have not responded to at least two prior treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that …

This study is a registry that will follow about 2950 adults in Germany with certain blood cancers (like CLL, DLBCL, and others). Researchers will collect information on the treatments people receive, how their disease progresses, and their quality of life. No new treatments are g…